Adapalene
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Adapalene: From Acne Treatment to Zinc, Elevated Plasma
One-Sentence Summary
Adapalene is a synthetic retinoid (RAR-β/γ agonist) used topically for acne treatment. The TxGNN model predicts it may be effective for Zinc, Elevated Plasma, however with 0 clinical trials and 0 publications currently supporting this direction — making this a purely model-driven hypothesis with no clinical corroboration at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acne vulgaris (topical retinoid) |
| Predicted New Indication | Zinc, Elevated Plasma |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L5 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, Adapalene is a third-generation synthetic retinoid that selectively binds to retinoic acid receptors RAR-β and RAR-γ. Its established efficacy in acne treatment is attributed to modulation of keratinocyte differentiation and anti-inflammatory activity rather than any known role in metal ion metabolism.
The proposed mechanistic link in this repurposing hypothesis is highly speculative. The hypothesised pathway is: Adapalene (as a RAR-β/γ agonist) → upregulation of metallothionein gene expression → metallothionein (a zinc-chelating protein) → theoretical reduction of free plasma zinc concentrations. Retinoids and zinc metabolism do share an indirect biological relationship — zinc is a cofactor for retinol-binding protein (RBP) — but the directionality and dose-response of any such interaction are not well characterised.
The TxGNN score of 0.9951 likely reflects the model capturing a knowledge-graph path: retinoid → metallothionein → zinc. However, this remains a graph-inference signal only. This pathway has never been directly validated in clinical or cell-based studies, and "zinc, elevated plasma" is a laboratory abnormality rather than a discrete clinical disease entity, making the therapeutic relevance of this prediction particularly uncertain.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Adapalene has no registered authorizations in New Zealand as of the data cutoff (2026-06-06).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is evidence level L5 — model inference only, with no supporting clinical trials or peer-reviewed literature. The proposed mechanism (retinoid → metallothionein → zinc chelation) is a highly speculative multi-step hypothesis that has not been tested in any experimental system, and the target condition ("zinc, elevated plasma") lacks a well-defined clinical disease framework for a repurposing study.
To proceed, the following is needed:
- Retrieve Adapalene's full mechanism of action data from DrugBank to confirm or refute the metallothionein upregulation hypothesis
- Conduct a targeted literature search for retinoid–zinc interactions in in vitro or animal models to assess whether any biological signal exists
- Define the clinical context more precisely: is "elevated plasma zinc" a standalone condition or secondary to another disease? This determines whether a therapeutic intervention is appropriate
- Obtain Taiwan/New Zealand package insert data to complete safety profiling before any forward-looking study design
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.